TNF-α, IL-6 and hsCRP in patients with melancholic, atypical and anxious depression: an antibody array analysis related to somatic symptoms

Abstract

BackgroundThe association between inflammation and major depressive disorder (MDD) remains poorly understood, given the heterogeneity of patients with MDD.AimsWe investigated inflammatory markers, such as interleukin (IL)-6, high-sensitivity C reactive protein (hsCRP) and tumour necrosis factor-α (TNF-α) in melancholic, atypical and anxious depression and explored whether baseline inflammatory protein levels could indicate prognosis.MethodsThe sample consisted of participants (aged 18–55 years) from a previously reported multicentre randomised controlled trial with a parallel-group design registered with ClinicalTrials.gov, including melancholic (n=44), atypical (n=37) and anxious (n=44) patients with depression and healthy controls (HCs) (n=33). Subtypes of MDD were classified according to the 30-item Inventory of Depressive Symptomatology, Self-Rated Version and the 17-item Hamilton Depression Rating Scale. Blood levels of TNF-α, IL-6 and hsCRP were assessed using antibody array analysis.ResultsPatients with MDD, classified according to melancholic, atypical and anxious depression subtypes, and HCs did not differ significantly in baseline TNF-α, IL-6 and hsCRP levels after adjustment. In patients with anxious depression, hsCRP levels increased significantly if they experienced no pain (adjusted (adj.) p=0.010) or mild to moderate pain (adj. p=0.038) compared with those with severe pain. However, the patients with anxious depression and severe pain showed a lower trend in hsCRP levels than patients with atypical depression who experienced severe pain (p=0.022; adj. p=0.155). Baseline TNF-α (adj. p=0.038) and IL-6 (adj. p=0.006) levels in patients in remission were significantly lower than those in patients with no remission among the participants with the atypical depression subtype at the eighth-week follow-up.ConclusionsThis study provides evidence of differences in inflammatory proteins in patients with varied symptoms among melancholic, atypical and anxious depression subtypes. Further studies on the immunoinflammatory mechanism underlying different subtypes of depression are expected for improved individualised therapy.Trial registration numberNCT03219008.

Causal associations between major depressive disorder and COVID-19

“…By using literature-based analysis, we explored potential mechanisms underlying the connection between MDD and COVID-19. Notably, the SARS-CoV-2 virus is capable of causing a cytokine storm, with the same primary players as in the neuroinflammatory phenotype seen in patients with MDD, such as tumour necrosis factor (TNF)-α and interleukin (IL)-6 37 38. In particular, IL-6 induces a variety of acute-phase proteins and worsens the inflammatory response, and its high expression increases mucus production and aggravates disease in patients with COVID-19 39.…”

Effect of postoperative application of esketamine on postoperative depression and postoperative analgesia in patients undergoing pancreatoduodenectomy: a randomized controlled trial protocol

“…Moreover, BDNF polymorphisms are associated with the antidepressant efficacy of ketamine in depressed patients [ 24 ]. TNF-α and IL-6 are inflammatory indicators and are strongly correlated with postoperative depression [ 26 ].…”

Mental stress, atheroma, myocardial ischaemia and injury: the link is inflammation

“… 49 50 Patients in remission from atypical depressive symptoms had lower levels of TNF-α and IL-6 compared with those with no remission. 51 However, well-conducted, large-scale trials with long follow-up on anti-inflammatory drugs are still unavailable, although numerous small studies have tested anti-inflammatory drugs in addition to conventional therapy for anxiety, depression and a variety of other conditions. Nevertheless, meta-analyses have suggested benefits for mental disorders with anti-inflammatory drugs.…”